Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Soluble GC stimulators and activators: Past, present and future
Peter Sandner, Markus Follmann, Eva Becker‐Pelster, et al.
British Journal of Pharmacology (2021) Vol. 181, Iss. 21, pp. 4130-4151
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions
Jun Ma, Yanan Li, Xiangyu Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 105
The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications
Tong Yue, Yu Shi, Sihui Luo, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 70
Effect of Avenciguat on Albuminuria in Patients with CKD
Hiddo J.L. Heerspink, David Cherney, Abdul Halim Abdul Gafor, et al.
Journal of the American Society of Nephrology (2024) Vol. 35, Iss. 9, pp. 1227-1239
Open Access | Times Cited: 15
The nitric oxide–soluble guanylate cyclase–cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase
Raymond L. Benza, Ekkehard Grünig, Peter Sandner, et al.
European Respiratory Review (2024) Vol. 33, Iss. 171, pp. 230183-230183
Open Access | Times Cited: 13
Runcaciguat activates soluble guanylyl cyclase via the histidine essential for heme binding and nitric oxide activation
Theresa Wittrien, Anne Rühle, Christin Elgert, et al.
Biochemical Pharmacology (2025) Vol. 232, pp. 116739-116739
Open Access | Times Cited: 1
Soluble guanylate cyclase stimulators and activators as potential antihypertensive drugs
Masashi Tawa, Keisuke Nakagawa, Mamoru Ohkita
Hypertension Research (2025)
Closed Access | Times Cited: 1
Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure
Filippos Triposkiadis, Αndrew Xanthopoulos, John Skoularigis, et al.
Heart Failure Reviews (2022) Vol. 27, Iss. 6, pp. 1991-2003
Closed Access | Times Cited: 31
Synthetic Approaches to the New Drugs Approved During 2021
Emma L. McInturff, Scott P. France, Carolyn A. Leverett, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10150-10201
Closed Access | Times Cited: 15
New Therapeutics for Heart Failure: Focusing on cGMP Signaling
Supachoke Mangmool, Ratchanee Duangrat, Warisara Parichatikanond, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12866-12866
Open Access | Times Cited: 14
Soluble Guanylyl Cyclase Activators—Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension
Grzegorz Grześk, Adrianna Witczyńska, Magdalena Węglarz, et al.
Molecules (2023) Vol. 28, Iss. 2, pp. 861-861
Open Access | Times Cited: 13
Vericiguat alleviates ventricular remodeling and arrhythmias in mouse models of myocardial infarction via CaMKII signaling
Tao Chen, Bin Kong, Wei Shuai, et al.
Life Sciences (2023) Vol. 334, pp. 122184-122184
Closed Access | Times Cited: 13
Isthmin-1 alleviates cardiac ischaemia/reperfusion injury through cGMP-PKG signalling pathway
Min Hu, Xin Zhang, Can Hu, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 9, pp. 1051-1064
Closed Access | Times Cited: 5
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy
Hema Kalyanaraman, Shyamsundar Pal China, Darren E. Casteel, et al.
Trends in Pharmacological Sciences (2025)
Closed Access
Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics
Daniel Stehle, Mariagiovanna Barresi, Jennifer Schulz, et al.
Pharmacology & Therapeutics (2023) Vol. 242, pp. 108337-108337
Closed Access | Times Cited: 12
Soluble guanylate cyclase as a direct target for pharmacologic mitigation of chronic kidney disease
Mia Jensen, Boye L. Jensen
Kidney International (2025) Vol. 107, Iss. 3, pp. 391-394
Closed Access
Worsening heart failure: progress, pitfalls, and perspectives
Fonseca Cândida, Baptista Rui, Franco Fátima, et al.
Heart Failure Reviews (2025)
Open Access
Cellular Factors That Shape the Activity or Function of Nitric Oxide-Stimulated Soluble Guanylyl Cyclase
Iraida Sharina, Emil Martin
Cells (2023) Vol. 12, Iss. 3, pp. 471-471
Open Access | Times Cited: 10
The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula
Olga Gawryś, Zuzana Husková, Petra Škaroupková, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 396, Iss. 12, pp. 3757-3773
Open Access | Times Cited: 10
First‐in‐human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS‐penetrant soluble guanylyl cyclase stimulator
Sebastiaan J. W. van Kraaij, Pim Gal, Laura Borghans, et al.
Clinical and Translational Science (2023) Vol. 16, Iss. 8, pp. 1381-1395
Open Access | Times Cited: 9
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat
Achim Fritsch, Michaela Meyer, Robert O. Blaustein, et al.
Clinical Pharmacokinetics (2024) Vol. 63, Iss. 6, pp. 751-771
Open Access | Times Cited: 3
Soluble guanylyl cyclase stimulators and activators: promising drugs for the treatment of hypertension?
Olga Gawryś, Petr Kala, Janusz Sadowski, et al.
European Journal of Pharmacology (2024), pp. 177175-177175
Closed Access | Times Cited: 3
Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases
Wei Huang, Yiyuan Chen, Ziqi Li, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10882-10882
Open Access | Times Cited: 14
A natural heme deficiency exists in biology that allows nitric oxide to control heme protein functions by regulating cellular heme distribution
Dennis J. Stuehr, Pranjal Biswas, Yue Dai, et al.
BioEssays (2023) Vol. 45, Iss. 8
Open Access | Times Cited: 8
The evolution of small molecule enzyme activators
Louise F. Dow, Alfie M. Case, Megan P. Paustian, et al.
RSC Medicinal Chemistry (2023) Vol. 14, Iss. 11, pp. 2206-2230
Open Access | Times Cited: 8
Soluble guanylyl cyclase: A novel target for the treatment of vascular cognitive impairment?
Ellis Nelissen, Melissa Schepers, Laura Ponsaerts, et al.
Pharmacological Research (2023) Vol. 197, pp. 106970-106970
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top